Key result
Combined novel biomarkers linked to ~83% higher risk of recurrent coronary events.
Why the study?
Conventional risk factors have limited ability to predict recurrent events in subjects with first-time coronary artery disease, motivating the search for novel biomarkers.
Case-Control (n=170)
Yes
Answers are grounded in this paper and cite their sources.
May support refined recurrent CAD risk stratification; leaves open prospective validation before clinical adoption.
Conventional risk factors have limited ability to predict recurrent events in subjects with first-time coronary artery disease (CAD). This aim of this study was to identify novel biomarkers using comparative global proteome analysis to improve the risk assessment for recurrent coronary events. We used samples from phase-I of the Indian Atherosclerosis Research Study (IARS), consisting of 2,332 subjects, of whom 772 were CAD-affected subjects, including 152 with recurrent events identified during a 5-year follow-up period. Global proteome analysis was performed on serum samples of 85 subjects with recurrent coronary events and 85 age- and gender-matched subjects with first-time CAD using surface-enhanced laser desorption ionization time-of-flight mass spectrometry with CM10 arrays. TagIdent was used for protein identification followed by validation by western blot analysis and ELISA. Data were analyzed by logistic analysis, Cox-regression, hazards ratio, C-statistics and combined-marker risk score using SPSS version-17 and R-package version-2.13.0 software. We identified 16 significantly differentially expressed protein peaks. Of these, 2 peaks corresponding to m/z 8588 and 1864 were identified as β-defensin-128 and histatin-3, belonging to the danger-recognizing peptide family, which exhibited a significant independent association with recurrent events (odds ratios of 7.49 and 1.4, respectively). C-statistics improved significantly from 0.677 for conventional risk factors alone to 0.800 (p-value=0.001) in combination with β-defensin-128 and histatin-3 with a hazards ratio of 1.833. A combined risk score of β-defensin-128 and histatin-3 could reclassify 112 out of the 170 subjects into intermediate- and high-risk groups. On the whole, our data indicate that β-defensin-128 and histatin-3 may be potential biomarkers whch may be used to improve risk the stratification for recurrent coronary events.
No takes yet. Share an insight, caveat, or question.
Ghatge et al. (2017) conducted a case-control in Coronary artery disease (CAD) (n=170). Elevated β-defensin-128 and histatin-3 levels vs. Lower biomarker levels / First-time CAD subjects without recurrent events was evaluated on Recurrent coronary events (HR 1.833, 95% CI 1.34-2.50, p=1.3x10-4). The combination of novel biomarkers β-defensin-128 and histatin-3 was independently associated with recurrent coronary events (HR 1.833) and significantly improved risk prediction over conventional risk factors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: